Enanta Pharmaceuticals, Inc.: updates and filings

ENTANASDAQHealthcare · Pharmaceutical Preparations

Price

$7.98

November 19, 2026Market cap $230M

What Ploutos Investor adds for Enanta Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 15 fiscal years, from FY2011
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
  • The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 82 daysAround Feb 10, 2027 · for Q1 2027

last Nov 16, 2026next Feb 10, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Nov 18, 2026 latest annualAug 12, 2026 latest quarterly
  • Nov 18, 2026Annual reportfor the period to Sep 30, 2026
    Form10-K
  • Nov 16, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 16, 2026Results of operations
    Form8-K
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 29, 2026Other material events
    Form8-K
  • Oct 28, 2026Officer or director change, Regulation FD disclosure
    Form8-K
  • Oct 27, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 10, 2026Results of operations
    Form8-K
  • Jul 2, 2026Material agreement entered
    Form8-K
  • Jun 23, 2026Other material events
    Form8-K
  • Jun 18, 2026Regulation FD disclosure
    Form8-K
  • May 13, 2026Shares registered for employees
    FormS-8
  • May 13, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 11, 2026Results of operations
    Form8-K
  • Mar 26, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Mar 26, 2026Other material events
    Form8-K
  • Mar 12, 2026Officer or director change, shareholder vote
    Form8-K
  • Feb 20, 2026Filing
    FormEFFECT
  • Feb 17, 2026Correspondence with the SEC
    FormCORRESP
  • Feb 17, 2026Letter from the SEC
    FormUPLOAD
  • Feb 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 11, 2026Shelf registration for future offerings
    FormS-3

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 21, 2002.

The full analysis

What do Enanta Pharmaceuticals's filings show?

The filings are where every one of Enanta Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.